Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 2 3Phase 1/2 2Phase NA 1Phase 3 1

Status

Recruiting 2Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Other solid neoplasm 3

Conditions

Breast Neoplasms 102Carcinoma, Non-Small-Cell Lung 93Multiple Myeloma 80Prostatic Neoplasms 74Colorectal Neoplasms 59Neoplasms 57Leukemia, Myeloid, Acute 56Lymphoma 48Squamous Cell Carcinoma of Head and Neck 43Lung Neoplasms 39Ovarian Neoplasms 38Melanoma 38Neoplasm Metastasis 36Pancreatic Neoplasms 35Lymphoma, Non-Hodgkin 35Carcinoma, Hepatocellular 34Lymphoma, Large B-Cell, Diffuse 33Sarcoma 31Head and Neck Neoplasms 31Urinary Bladder Neoplasms 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 29Carcinoma, Renal Cell 29Leukemia, Lymphocytic, Chronic, B-Cell 28Hodgkin Disease 28Endometrial Neoplasms 28Triple Negative Breast Neoplasms 27Myelodysplastic Syndromes 26Recurrence 25Hematologic Neoplasms 25Glioma 25

Interventions

pembrolizumab 1Pharmacogenomic Testing 1Brentuximab Vedotin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Mesothelioma, Malignant × 30 days × Clear all
NCT06477419 2026-05-28

A Study of Sacituzumab Govitecan in People With Mesothelioma

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
33 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

NCT03007030 2026-05-15

Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery

M.D. Anderson Cancer Center

Phase 2 Recruiting
55 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT02399371 2026-05-08

Pembrolizumab in Treating Patients With Malignant Mesothelioma

University of Chicago

Phase 2 Completed
65 enrolled 12 charts
Other solid neoplasmThoracic

Mesothelioma, Malignant, Solitary Fibrous Tumor, Pleural

Data powered by HemOnc (CC BY 4.0) Colophon âš¡